‹ ›
MYP_032553
← PREVIOUS NEXT → BACK
Basic Information
Peginterferon alfa-2a
Anticancer
Antimicrobial
Antiviral
Antiviral ▸ Anti-Hepatitis virus ▸ Anti-HBV
Antiviral ▸ Anti-Hepatitis virus ▸ Anti-HCV
Immunology ▸ Immune modulation ▸ Immunomodulatory activity
Immunology ▸ Immunomodulation ▸ Immunogen
Immunology ▸ Immunomodulation ▸ Immunosuppressive
Therapeutic / Biomedical activity ▸ Enzyme replacement therapy
Standard
165 amino acids
C860H1353N229O255S9
Standard
Sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Physicochemical Analysis
19268.91 Da
5.99
-1.98
-2.45
-0.0120
-0.34
0.62
-0.04
53.94
85.70
0.1030
18450.00
18700.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
7885.30
-75.90
277.0
265.0
654.0
1353.0
27.0
180.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0084776 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Escherichia coli [Bacterium]
Interferon
9606; 562
Structure & Mods
branched peptide architecture [Branched]
canonical L-amino-acid peptide [L]
PEGylation, Phosphorylation
Bio-Activity Profile
Antimicrobial Antiviral Anticancer Immunomodulatory Enzyme replacement Vaccine Immunogen
Terminal half life is 164 hours (range 84 to 353 hours).
Evidence URLhttps://patents.google.com/patent/CA2203480/en PatentCA2203480
RECORD: Rec_0098296 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]; Escherichia coli [Bacterium]
PEGylated interferon
9606;562
Structure & Mods
linear peptide/protein therapeutic [Linear]
noncanonical stereochemical or chemical modification [Modified]
PEGylation
Bio-Activity Profile
Immunomodulatory Immunosuppressive Antiviral
approx. 40 h (range 22 to 60 h) in patients with HCV infection
PaperPubMed-linked source references: PMID:26280154; PMID:26261238; PMID:25771464; PMID:25117425; PMID:25068004; PMID:24974131; PMID:24119723; PMID:24059964; PMID:23746377 PMID26280154;26261238;25771464;25117425;25068004;24974131;24119723;24059964;23746377 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/26280154/ PatentCA1341567
RECORD: Rec_0342178 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
Interferon
9606
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Anti-HBV Immunomodulatory
Hepatitis B virus
PMID25585348 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/25585348/
RECORD: Rec_0352294 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
Interferon
9606
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Anti-HCV Immunomodulatory
Hepatitis C virus
PMID25585348 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/25585348/